NASDAQ:IPSC Century Therapeutics Q2 2026 Earnings Results & Report $1.72 +0.05 (+2.68%) As of 12:35 PM Eastern This is a fair market value price provided by Massive. Learn more. Century Therapeutics missed analyst earnings expectations in its Q2 2026 results, released August 12, 2026. The company reported EPS of -$0.17 versus the -$0.11 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ2 2026Report DateAugust 12, 2026TimeBefore Market OpensConference Call7:00 AM ET Century Therapeutics EPS ResultsActual EPS-$0.17Consensus EPS -$0.11Beat/MissMissed by -$0.06One Year Ago EPSN/AEPS Beat Rate6 of last 8 quartersCentury Therapeutics Revenue ResultsActual RevenueN/AExpected Revenue$2.17 millionBeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsCentury Therapeutics' Q3 2026 earnings is estimated for Thursday, November 12, 2026, based on past reporting schedules, with a conference call scheduled on Tuesday, November 17, 2026 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Century Therapeutics Q2 2026 Earnings FAQ Did Century Therapeutics beat earnings estimates for Q2 2026? Century Therapeutics (NASDAQ:IPSC) reported earnings of -$0.17 per share for Q2 2026, missing the consensus estimate of -$0.11. The report was announced on Wednesday, August 12, 2026. When is Century Therapeutics' next earnings date? Century Therapeutics' next earnings date is estimated for Thursday, November 12, 2026. MarketBeat tracks confirmed and estimated earnings dates for Century Therapeutics on the company's earnings history page. Century Therapeutics Earnings HeadlinesCentury Therapeutics (IPSC) Expected to Release Quarterly Earnings on ThursdayNovember 11 at 3:52 AM | americanbankingnews.comCentury Therapeutics (NASDAQ:IPSC) Rating Lowered to "Sell" at Wall Street ZenOctober 31, 2026 | americanbankingnews.comA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief. It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live.November 11 at 1:00 AM | Porter & Company (Ad)Century Therapeutics to Attend 2026 Jefferies Global Healthcare Conference in LondonOctober 14, 2026 | globenewswire.comCentury Therapeutics CNTY-813 Demonstrates Continued Advancement toward the Clinic Via Nonclinical Data Presented at EASD 2026October 5, 2026 | marketscreener.comMCentury Therapeutics, Inc. Presents Nonclinical Data For CNTY-813 At EASDOctober 3, 2026 | marketscreener.comMSee More Century Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Century Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Century Therapeutics and other key companies, straight to your email. Email Address About Century TherapeuticsCentury Therapeutics (NASDAQ:IPSC) is a biotechnology company focused on developing allogeneic, or “off-the-shelf,” cell therapies for cancer. The company uses induced pluripotent stem cell (iPSC) technology to create immune-effector cells, including natural killer (NK) cells and T cells, that can be engineered to recognize and attack tumor cells. Century’s pipeline has included product candidates designed for hematologic malignancies and solid tumors. Its programs incorporate technologies intended to improve the persistence, activity, and scalability of engineered immune cells, with development efforts involving targets such as CD19 and other tumor-associated antigens. The company’s candidates are investigational and are being evaluated through preclinical and clinical research rather than marketed as approved treatments. Founded in 2018 and headquartered in Philadelphia, Pennsylvania, Century Therapeutics was established to advance iPSC-derived cell therapies using a platform intended to support standardized manufacturing and repeatable production. The company conducts research and clinical development primarily in the United States and works with collaborators and research organizations in the biotechnology and cell-therapy sectors.View Century Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Amazon's Rally Is Outpacing Big Tech, But Can AWS Justify the AI Spending?Aehr Test Systems Notches Another Post-Earnings Win as Sales Triple on AI DemandThe Trade Desk Beats on Revenue, But the Fine Print MattersWhy Kinder Morgan's Chairman Just Bought $15 Million in StockA $4 Billion Jolt: NRG Energy Powers Data Center Ambitions3 Stocks Wall Street Likes More Than the Market DoesD-Wave Quantum Has Long-Term Potential, But Is Now the Time to Buy? Upcoming Earnings Brookfield (11/12/2026)NU (11/12/2026)Applied Materials (11/12/2026)Cisco Systems (11/12/2026)Mizuho Financial Group (11/13/2026)Mitsubishi UFJ Financial Group (11/13/2026)Sumitomo Mitsui Financial Group (11/13/2026)Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
